Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03092856 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 30, 2026 to Dec 31, 2026
    • Study sites: 10 to 9
    • Study completion date: Dec 31, 2026 to Dec 31, 2027
    v15
  2. Primary completion date: Dec 31, 2025 to Jun 30, 2026v14
  3. Primary completion date: Jul 19, 2025 to Dec 31, 2025
    • Study completion date: Jul 19, 2026 to Dec 31, 2026
    v13
  4. Primary completion date: Jul 19, 2024 to Jul 19, 2025
    • Study completion date: Jul 19, 2025 to Jul 19, 2026
    v12
  5. Primary completion date: Jul 19, 2023 to Jul 19, 2024
    • Study completion date: Jul 19, 2024 to Jul 19, 2025
    v11
Show 9 earlier versionsHide 9 earlier versions
  1. Primary completion date: Jul 19, 2022 to Jul 19, 2023v10 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 104 to confirmed 62
    • Study completion date: Jul 19, 2023 to Jul 19, 2024
    • Site details revised at 10 of 10 sites
  2. Primary completion date: Jul 19, 2021 to Jul 19, 2022
    • Study completion date: Jul 19, 2022 to Jul 19, 2023
    v9
  3. Primary completion date: Jul 19, 2020 to Jul 19, 2021
    • Study completion date: Jul 19, 2021 to Jul 19, 2022
    • Site details revised at 1 of 10 sites
    v8
  4. Study sites: 5 to 10v7
  5. Re-verified, no change to tracked fieldsv6
  6. Trial status: Not Yet Recruiting to Recruitingv5 Show 4 more changesShow less
    • Primary completion date: Sep 1, 2020 to Jul 19, 2020
    • Study completion date: Sep 1, 2021 to Jul 19, 2021
    • Start date changed from estimate of Sep 1, 2017 to Jul 19, 2017
    • Site details revised at 5 of 5 sites
  7. Start date: Jul 10, 2017 to Sep 1, 2017
    • Primary completion date: Jul 10, 2020 to Sep 1, 2020
    • Study completion date: Jul 10, 2021 to Sep 1, 2021
    • Secondary endpoints: 3 to 2
    v4
  8. Start date: May 15, 2017 to Jul 10, 2017
    • Primary completion date: May 15, 2020 to Jul 10, 2020
    • Study completion date: May 15, 2021 to Jul 10, 2021
    v3
  9. Start date: Mar 27, 2017 to May 15, 2017
    • Primary completion date: Mar 27, 2020 to May 15, 2020
    • Study completion date: Mar 27, 2021 to May 15, 2021
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body. Biological therapies, such as anti-OX40 antibody PF-04518600, use substances made from living organisms that may may stimulate the immune system in different ways and stop tumor cells from growing. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving axitinib with or without anti-OX40 antibody PF-04518600 may work better in treating patients with kidney cancer.
Trial Details
NCT Number NCT03092856
Lead Sponsor University of Southern California
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Related terms Carcinoma, Renal Cell
Enrollment 62 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov